tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Pelthos Therapeutics reports Q2 EPS ($5.38) vs ($3.07) last year

Scott Plesha, CEO of Pelthos, stated, “The past month has been defined by focus and execution. Since completing the Merger and closing our private placement financing in early July, we have successfully built out our commercial organization and launched our novel treatment for molluscum into the market. These early achievements position us for an exciting next chapter of growth and innovation.”

Meet Your ETF AI Analyst

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1